Optimi Health (OPTI) Registration filing summary

Company overview and business model

• Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Vertically integrated with two 10,000 sq. ft. production facilities in Princeton, BC, operating under a Drug Establishment Licence (DEL) and Dealer's Licence (DL).

• Products are available in Australia (prescription for PTSD and TRD), Canada (Special Access Program), and for clinical trials in Israel; U.S. market entry is pending regulatory changes.

• Focus on scaling production, regulatory compliance, and expanding into new markets such as the U.S. and Israel.

• Winding down nutraceutical business to focus on pharmaceutical-grade manufacturing.

Financial performance and metrics

• Fiscal year ended September 30, 2025: revenue C$426,301 (US$306,097), net loss C$3,712,031 (US$2,665,349), accumulated deficit C$27,241,680 (US$20,001,233).

• Three months ended December 31, 2025: revenue C$232,700, net loss C$1,553,975.

• As of December 31, 2025: cash and cash equivalents C$491,750, total assets C$14,236,203, total liabilities C$9,219,190, shareholders' equity C$5,017,013.

• Company has a history of operating losses and has not achieved profitability; future operations depend on raising additional capital.

Use of proceeds and capital allocation

• Estimated net proceeds of US$12.2 million (or US$14.3 million if over-allotment is exercised) based on a US$6.00 per Unit offering price.

• 28.7% for scaling production and distribution in current markets, 18.0% for preparing market entry to Israel and the U.S., 53.3% for general working capital and operating expenses.

• Management has broad discretion over use of proceeds; additional funds may be needed for U.S. market entry beyond the next 12 months.